Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/u445773645/domains/acmcasereport.org/public_html/wp-includes/functions.php on line 6114
Multicentric and Prospective Trial of Vulvovaginitis Treatment Comparing Propionibacterium Extract [Immunovag®] With Metronidazole Plus Clotrimazole [Meclon®] - Annals of Clinical and Medical Case Reports (ISSN 2639-8109)

Call

+1 7755157689

Email

submission@acmcasereport.us

Multicentric and Prospective Trial of Vulvovaginitis Treatment Comparing Propionibacterium Extract [Immunovag®] With Metronidazole Plus Clotrimazole [Meclon®]

Start your future today

Sign up to get application tips, explore student stories and find out about our latest events.

Start your future today

Sign up to get application tips, explore student stories and find out about our latest events.

Vulvo-Vaginal Infections [VVI] strongly interferes with the wom an’s quality of life. Antibiotic treatments, alone or combined with an antifungal compound, are commonly and successfully used. Nevertheless, they can impair genital microbiota, with long-term disorders, such as a flare-up of genital disturbances due to chang es of endogenous lactobacilli. Alternatively, probiotics have been proposed. This prospective multicenter double-arm study, per formed in 72 premenopausal women diagnosed with VVI, whose etiology was Gardnerella Vaginalis (n=9), Candida Albicans (n=21), or Bacterial Vaginosis (n=42), was performed to com pare the clinical efficacy of a short-term treatment with a vaginal gel containing the bacteria lysate obtained by Propionibacterium acnes [Immunovag®, Depofarma, Mogliano Veneto, Italy] given for 5 days (n=40) with that of vaginal suppositories containing metronidazole and clotrimazole [Meclon®, Alfasigma SPA, Bo logna, Italy] given for 6 days (n=32). The study was conducted at the gynecological Departments of the University-Hospitals of Cagliari, Catania, Catanzaro, Genova and Modena – Reggio Emilia [Italy]. At post-treatment evaluation (10 days from the screening and randomization), regardless of VVI etiology and type of treat ment, a significant decrease (p

Post Related

error: Content is protected !!